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processing and cell surface expression. Since development and
progression of tumors is not only dependent on cancer cells
themselves but also on the active contribution of the stromal
cells, e.g. by secreting growth supporting factors, enzymes
degrading the extracellular matrix or angiogenic factors, the
tumor stroma may also serve as a target for immune interven-
tion. To this end several antigens have been identified which
are induced or upregulated on the tumor stroma. Tumor
stroma-associated antigens are characterized by an otherwise
restricted expression pattern, particularly with respect to differ-
entiated tissues, and they have been successfully targeted by
passive and active immunotherapy in preclinical models. More-
over, some of these strategies have already been translated into
clinical trials.
The work is supported by the grant KFO 124-1/2 of the Deut-
sche Forschungsgemeinschaft.
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S33. MOLECULAR PHENOTYPING OF MINIMAL RESIDUAL
DISEASE IN SOLID CANCER – DEFINING THE MARKERS FOR
TUMOR PROGRESSION?
Klaus Pantel. Institut fu¨r Tumorbiologie, Universita¨tsklinikum
Hamburg-Eppendorf, Germany.
Metastasis is the major cause of deaths in patients with solid
tumors. Occult micrometastatic spread of tumor cells might be
the seed for the occurrence of overt metastases in distant
organs within the years following successful surgical resection
of the primary tumor. The two major approaches to detect such
‘‘minimal residual disease’’ are immunocytochemical staining
and polymerase chain reaction analysis. These assays are sensi-
tive enough to detect a single disseminated tumor cell (DTC) in
the background of millions of normal cells [Pantel and Braken-
hoff. Nat Rev Cancer 2004;4:1–9]. For epithelial tumors, cytokera-
tins have become the best marker for the immunocytochemical
detection of DTCs in blood, lymph nodes and bone marrow
(BM).
Micrometastatic cells in BM can be easily collected from the
iliac crest, and BM seems to be a common homing organ for DTCs
derived from various types of malignant epithelial tumors (e.g.,
breast, lung, prostate or colorectal cancer). DTCs are present in
BM samples of 20–40% of patients even in the absence of lymph
node metastases (stage N0) or clinical signs of overt distant
metastases (stage M0). A pooled analysis on 4703 breast cancer
patients [Braun et al., NEJM 2005;353:793–802] has shown that
the detection of DTC in BM is a marker for an increased risk to
develop metastatic relapse. The molecular and biochemical char-
acterization of DTCs helps to identify progression markers
towards overt metastases and new therapeutic targets for thera-
pies that are specifically directed against minimal residual dis-
ease. This information may refine the current DTC detection
approaches, which the major goal of the EU-funded consortium
‘‘DISMAL’’ coordinated by K.P.
doi:10.1016/j.ejcsup.2006.04.034
S34. TARGETING Plk1 FOR CANCER THERAPY
Mathias Schmidt, Hans-Peter Hofmann, Karl Sanders, Volker
Gekeler, Thomas Beckers. Altana Pharma AG, Therapeutic Area
Oncology, Byk-Gulden Str. 1, D-78467 Konstanz, Germany.
A stringent control of mitosis is mandatory to warrant the
accurate segregation of sister chromatids in dividing cells.
Eukaryotic cells have evolved sophisticated mechanisms to
monitor faithful progression through each phase of mitosis in
order to prevent the occurrence of aneuploid daughter cells.
Polo like kinase 1 (Plk1) has been identified to be a key player
for G2-M transition and mitotic progression in both, normal
and tumor cells. Multiple essential roles have been assigned
to Plk1 at the entry into M-phase, mitotic spindle formation,
condensation and separation of chromosomes, exit from mito-
sis by activation of the anaphase-promoting complex and in
cytokinesis.
We have employed chimeric antisense oligonucleotides and
siRNA to investigate the molecular alterations after targeted
interference with Plk1 in a multitude of human cancer cells.
Suppression of Plk1 mRNA inevitably resulted in a dramatic
increase of the mitotic index followed by the onset of apoptosis.
Mitotically arrested cells displayed randomly separated con-
densed chromosomes and the occurrence of multiple spindle
poles with well-formed asters. Induction of apoptosis was
strictly dependent on cell cycle progression: Genetically engi-
neered RKO human colon adenocarcinoma cells with inducible
expression of the cdk inhibitor p27Kip1 were completely refrac-
tory to Plk1 depletion-induced apoptosis when they were
arrested in the G1 phase of the cell cycle. Various mitotic mark-
ers including MPM-2, cdc25c, cyclinB1, or phospho-histone H3
were investigated to explore the molecular consequences of
Plk1 depletion. While most marker proteins only showed altera-
tions typical for mitosis, modifications of cdc25c allowed distinc-
tion between mitotic targeting via Plk1 or via other mechanisms,
such as microtubule inhibitors. cdc25c was fully phosphorylated
solely in paclitaxel-treated cells, while it was only partially
phosphorylated in Plk1 depleted cells despite the fact that both
treatments caused a profound mitotic arrest. This differential
phosphorylation of cdc25c was used to test whether a pharma-
cological inhibitor of Plk1 kinase activity would exert the same
cellular effects as interference with Plk1 on an mRNA level. In
deed, pharmacological intervention with Plk1 using a specific
Plk1 kinase inhibitor induced exactly the same molecular altera-
tions and displayed the cell cycle-dependent cytotoxicity as Plk1
interference on an mRNA level. Taken together, these data sub-
stantiate the attractiveness of Plk1 as candidate for mitotic tar-
geting of cancers.
doi:10.1016/j.ejcsup.2006.04.035
S35. REGULATION OF UCN-01 INDUCED MITOTIC CELL DEATH
BY PRO- AND ANTI-APOPTOTIC PATHWAYS
Celia Vogel, Christian Hager, Holger Bastians. Philipps University
Marburg, Institute for Molecular Biology and Tumor Research (IMT),
Marburg, Germany.
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The concept of ‘‘G2 checkpoint abrogation’’ in combination with
various chemotherapeutic drugs is currently successfully
explored in clinical trials. The anti-cancer drug UCN-01 allows
the entry into mitosis in the presence of DNA damage selectively
in p53 defective tumor cells.
We show here that this leads to a mitotic arrest and to the
activation of a branch of the mitotic spindle checkpoint that mon-
itors the lack of tension across kinetochores involving the func-
tion of Mad2, Bub1, BubR1, Mps1, Aurora B and survivin.
Subsequently mitotic cell death, also known as ‘‘mitotic catastro-
phe’’, is induced, which potentiates the efficacy of standard che-
motherapy. Interestingly, mitotic cell death is associated with the
activation of the mitochondria associated apoptosis pathway,
thus, we refer to it as mitotic apoptosis. Importantly, while the
mitotic arrest in response to UCN-01 is dependent on the spindle
checkpoint, only the checkpoint component Mad2 is required for
the execution of mitotic apoptosis suggesting that Mad2 might
have an additional function as a pro-apoptotic protein. Signifi-
cantly, the mitotic apoptosis is counteracted by a survivin depen-
dent survival pathway. Thus, the mitotic apoptosis is a result of a
balance between pro- and anti-apoptotic pathways. Most impor-
tantly, pharmacologiocal interference with Aurora B, CDK1 or
PI3-kinase modulating the levels of survivin leads to a significant
increase of apoptosis in response to UCN-01. Thus, our results
suggest a highly improved strategy for anti-cancer treatment
using UCN-01 and abrogators of a mitotic survivin dependent sur-
vivial pathway without neglecting the selectivity of UCN-01 for
p53 defective cancer cells.
doi:10.1016/j.ejcsup.2006.04.036
S36. VIRAL ONCOGENES CAUSING HUMAN CANCERS
Harald zur Hausen. Deutsches Krebsforschungszentrum, Im
Neuenheimer Feld 280, 69120 Heidelberg, Germany.
Research of the past 25 years resulted in the identification of a
number of infectious agents engaged in the etiology of in part
very common human cancers. Among the latter are cervical
cancer and hepatocellular carcinomas. Members of several dif-
ferent virus families possess oncogenic potential: these are pap-
illomaviruses (e.g. HPV 16 and 18), herpes group viruses
(Epstein-Barr virus and human herpesvirus type 8), Hepatitis B
and Hepatitis C virus, Human T-lymphotropic retrovirus type 1
(HTLV-1). Most of these agents contain oncogenes and act as
‘‘direct carcinogens’’. The functions of these oncogenes have
been partially characterized and will be discussed. Humans
and their cells infected by these viruses are commonly able to
cope with these infections by intra- and intercellular surveil-
lance mechanisms or by immunological interference. Cancer
development requires a modification of genes within the signal-
ling pathways regulating the intra- and intercellular defense.
Part of the modifications of cellular genes is also mediated by
viral oncogenes.
Besides direct carcinogenic functions via oncogenes, other
agents contribute to human cancer by rather indirect modes.
This seems to be the case in hepatitis B and C infections where
the induction of oxygen radicals apparently plays a significant
role in cancer induction. Human immunodeficiency viruses
(HIV) promote cancer induction by other viruses due to the
induction of immunosuppression. Possible other mechanisms
of indirect carcinogenesis by infectious agents will also be
discussed.
doi:10.1016/j.ejcsup.2006.04.037
S37. ONCOPROTECTIVE PARVOVIRUSES IN CANCER THERAPY
Jean Rommelaere. Deutsches Krebsforschungszentrum, Abt. F010
and INSERM U701, Heidelberg, Germany.
As a result of their oncotropism, oncolytic effect and low inflam-
matory activity, some autonomous parvoviruses open up new
prospects to the fight against cancer and were tested for their
safety in pilot phase I clinical trials. Preclinical studies in animal
models showed that the parvoviruses H-1PV and MVM are
endowed with a genuine oncosuppressive capacity, for which var-
ious tumours can be targets. However, the antineoplastic poten-
tial of these agents is insufficient, in many instances, for
tumours to irreversibly regress. Efforts are thus made to improve
the oncosuppressive activity of parvoviruses, using different
strategies. On the one hand, discrete modifications are intro-
duced into the parvoviral genome so as to keep its infectiousness
while stimulating its antineoplastic properties. Parvovirus
mutants were engineered so that their capacity for tumour cell
lysis or immune cell activation is enhanced. On the other hand,
parvoviruses are used as vectors to generate recombinants that
are able to deliver therapeutic transgenes in target cells. MVM
and H-1PV-based vectors transducing and expressing anti-angio-
genic and/or immunomodulating factors were more particularly
produced. Appropriate combinations of these recombinant vec-
tors were found to efficiently suppress highly vascularised
tumours, e.g. gliomas, in animal models. On the basis of these
data, the promise of the application of parvoviruses to cancer
viro- and gene therapy will be discussed.
doi:10.1016/j.ejcsup.2006.04.038
S38. PROPHYLACTIC VACCINES AGAINST CERVICAL CANCER
Lutz Gissmann. DKFZ, Heidelberg, Germany.
Since several years it has been accepted that persistent infection
with certain (so called-high risk: HR) types of Human papillom-
aviruses (HPV) represents a strong risk factor for cervical cancer.
The most frequent HR HPV types 16 and 18 account for about
70% of this tumour, which is the second most frequent malig-
nancy in women worldwide. Several studies in animal papillo-
mavirus models revealed that protection against infection is
conferred by neutralizing antibodies directed against conforma-
tional epitopes of the major structural protein L1. Such antibod-
ies can most efficiently be induced by immunization with virus-
like particles (VLP) that assemble spontaneously following
expression of L1 in recombinant vectors. Large-scale production
of HPV 16 and 18 VLPs proved to be successful facilitating, a few
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